IQVIA Holdings, Inc. Common Stock (IQV)

IQVIA (NYSE:IQV) reported third-quarter results that exceeded the high end of its guidance ranges, supported by accelerating organic growth in its Commercial Solutions and R&D Solutions businesses, higher clinical win rates and strong free cash flow. Revenue totaled $4.43 billion, up 8.0% year

Revenue hit $4.4 billion with 8% growth; net new bookings surged 15% year over year.

Clinical research company IQVIA (NYSE: IQV) reported Q3 2026 results exceeding the market’s revenue expectations, with revenue up 8% year on year to $4.43 bi...

Clinical research company IQVIA (NYSE: IQV) will be reporting results this Tuesday before market open. Here’s what to expect. IQVIA beat analysts’ revenue ex...

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit...

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on hi...

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...

The past six months have been a windfall for IQVIA’s shareholders. The company’s stock price has jumped 50%, hitting $267.77 per share. This was partly thank...

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services ind...

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are...

IQVIA’s second quarter was characterized by broad-based growth and accelerating demand across its clinical and commercial businesses, with market participant...

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, pos...

This insider disposed of 16% of direct holdings at $245.21 per share, while maintaining nearly 3,000 shares valued at $740,000.

Sherbet's disposition leaves him with 20,999 directly held shares valued at $5.2 million as IQVIA trades near $238.

Bousbib exercised expiring stock appreciation rights while maintaining about 1.4 million shares in total beneficial ownership.

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, u...

Clinical research company IQVIA (NYSE: IQV) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 8.7% year on year to $4.37 billi...

IQVIA (NYSE:IQV) reported second-quarter results that exceeded the high end of its guidance, supported by accelerating organic revenue growth, higher R&D Solutions bookings and operational productivity gains. The company also raised its full-year outlook for revenue, adjusted EBITDA and adjusted dil